Gerdau S.A. Common Stock vs Neurocrine Biosciences Inc — how do they compare? Gerdau S.A. Common Stock trades at $4.94 (market cap $9.38B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Gerdau S.A. Common Stock pays a 3.59% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gerdau S.A. Common Stock for 0 Days and Neurocrine Biosciences Inc for 23 Days on average.
| GGB | NBIX | |
|---|---|---|
Market Cap | $9.38B | $14.60B |
Volume | 13,301,134 | 1,075,694 |
Sector | Basic Materials | Health |
52-Week High | $5.17 | $185.50 |
52-Week Low | $3.15 | $123.10 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $11.33B | $14.61B |
Dividend Yield | 3.59% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Gerdau is a steel producer with operations across the Americas. It makes long steel, specialty steel, and other products for construction and industrial markets.
Read more on GGB →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →